Finn RS, Crown J, Lang I, et al. Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol. 35, 2017 (suppl; abstr 1001).
PARP-remmers waardevolle toevoeging aan eerstelijnsbehandeling ovariumcarcinoom
nov 2019 | Gynaecologische oncologie